Cargando…

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most po...

Descripción completa

Detalles Bibliográficos
Autores principales: Woopen, Christina, Schleußner, Katharina, Akgün, Katja, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256163/
https://www.ncbi.nlm.nih.gov/pubmed/34234787
http://dx.doi.org/10.3389/fimmu.2021.701752
_version_ 1783718044810346496
author Woopen, Christina
Schleußner, Katharina
Akgün, Katja
Ziemssen, Tjalf
author_facet Woopen, Christina
Schleußner, Katharina
Akgün, Katja
Ziemssen, Tjalf
author_sort Woopen, Christina
collection PubMed
description For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most potent escape strategies from the pandemic and multiple vaccines are already in clinical use. However, there is still a lot of insecurity about the safety and efficacy of vaccines in patients with autoimmune diseases like multiple sclerosis (MS), especially under treatment with immunomodulatory or immunosuppressive drugs. We propose strategic approaches to SARS-CoV-2 vaccination management in MS patients and encourage fellow physicians to measure the immune response in their patients. Notably, both humoral and cellular responses should be considered since the immunological equivalent for protection from SARS-CoV-2 after infection or vaccination still remains undefined and will most likely involve antiviral cellular immunity. It is important to gain insights into the vaccine response of immunocompromised patients in order to be able to deduce sensible strategies for vaccination in the future.
format Online
Article
Text
id pubmed-8256163
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82561632021-07-06 Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Woopen, Christina Schleußner, Katharina Akgün, Katja Ziemssen, Tjalf Front Immunol Immunology For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most potent escape strategies from the pandemic and multiple vaccines are already in clinical use. However, there is still a lot of insecurity about the safety and efficacy of vaccines in patients with autoimmune diseases like multiple sclerosis (MS), especially under treatment with immunomodulatory or immunosuppressive drugs. We propose strategic approaches to SARS-CoV-2 vaccination management in MS patients and encourage fellow physicians to measure the immune response in their patients. Notably, both humoral and cellular responses should be considered since the immunological equivalent for protection from SARS-CoV-2 after infection or vaccination still remains undefined and will most likely involve antiviral cellular immunity. It is important to gain insights into the vaccine response of immunocompromised patients in order to be able to deduce sensible strategies for vaccination in the future. Frontiers Media S.A. 2021-06-21 /pmc/articles/PMC8256163/ /pubmed/34234787 http://dx.doi.org/10.3389/fimmu.2021.701752 Text en Copyright © 2021 Woopen, Schleußner, Akgün and Ziemssen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Woopen, Christina
Schleußner, Katharina
Akgün, Katja
Ziemssen, Tjalf
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title_full Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title_fullStr Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title_full_unstemmed Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title_short Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
title_sort approach to sars-cov-2 vaccination in patients with multiple sclerosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256163/
https://www.ncbi.nlm.nih.gov/pubmed/34234787
http://dx.doi.org/10.3389/fimmu.2021.701752
work_keys_str_mv AT woopenchristina approachtosarscov2vaccinationinpatientswithmultiplesclerosis
AT schleußnerkatharina approachtosarscov2vaccinationinpatientswithmultiplesclerosis
AT akgunkatja approachtosarscov2vaccinationinpatientswithmultiplesclerosis
AT ziemssentjalf approachtosarscov2vaccinationinpatientswithmultiplesclerosis